Egetis Therapeutics Agrees to Sell Priority Review Voucher for USD 190 Million

Bitget2026/11/04 07:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Egetis Therapeutics today agreed to sell its Rare Pediatric Disease Priority Review Voucher for USD 190 million, approximately SEK 1.9 billion.
Former owners of subsidiary Rare Thyroid Therapeutics International are entitled to approximately 50% of net proceeds under the 2020 EMCITATE acquisition earnout.
Closing remains subject to customary conditions, including expiration of the applicable Hart-Scott-Rodino antitrust waiting period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Egetis Therapeutics Agrees to Sell Priority Review Voucher for USD 190 Million

You may also like

Crypto prices